NO20054141D0 - Substituerte 2-(diaza-bicykloalkyl)pyrimidonderivater - Google Patents

Substituerte 2-(diaza-bicykloalkyl)pyrimidonderivater

Info

Publication number
NO20054141D0
NO20054141D0 NO20054141A NO20054141A NO20054141D0 NO 20054141 D0 NO20054141 D0 NO 20054141D0 NO 20054141 A NO20054141 A NO 20054141A NO 20054141 A NO20054141 A NO 20054141A NO 20054141 D0 NO20054141 D0 NO 20054141D0
Authority
NO
Norway
Prior art keywords
bicycloalkyl
diaza
substituted
pyrimidone derivatives
pyrimidone
Prior art date
Application number
NO20054141A
Other languages
English (en)
Other versions
NO20054141L (no
Inventor
Alistair William Lochead
Mourad Saady
Franck Slowinski
Philippe Yaiche
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP03290570A external-priority patent/EP1454910A1/en
Priority claimed from EP20030290571 external-priority patent/EP1454908B1/en
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of NO20054141D0 publication Critical patent/NO20054141D0/no
Publication of NO20054141L publication Critical patent/NO20054141L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
NO20054141A 2003-03-07 2005-09-06 2-(diazabicykloalkyl)pyrimidonderivat, anvendelser derav for fremstilling av et medikament, medikament omfattende en slik forbindelse og mellomproduktforbindelse NO20054141L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03290570A EP1454910A1 (en) 2003-03-07 2003-03-07 Substituted pyrimidinyl-2-(diaza-bicyclo-alkyl)-pyrimidone derivatives
EP20030290571 EP1454908B1 (en) 2003-03-07 2003-03-07 Substituted pyridinyl-2-(diaza-bicyclo-alkyl)-pyrimidinone derivatives
PCT/EP2004/003050 WO2004078759A1 (en) 2003-03-07 2004-03-05 Substituted 2-(diaza-bicyclo-alkyl)-pyrimidone derivatives

Publications (2)

Publication Number Publication Date
NO20054141D0 true NO20054141D0 (no) 2005-09-06
NO20054141L NO20054141L (no) 2005-12-07

Family

ID=32963795

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054141A NO20054141L (no) 2003-03-07 2005-09-06 2-(diazabicykloalkyl)pyrimidonderivat, anvendelser derav for fremstilling av et medikament, medikament omfattende en slik forbindelse og mellomproduktforbindelse

Country Status (23)

Country Link
US (2) US7211581B2 (no)
EP (1) EP1603910B1 (no)
JP (1) JP4778890B2 (no)
KR (1) KR101072159B1 (no)
AR (1) AR043486A1 (no)
AT (1) ATE440844T1 (no)
AU (1) AU2004218249B2 (no)
BR (1) BRPI0408186A (no)
CA (1) CA2516934C (no)
CY (1) CY1111132T1 (no)
DE (1) DE602004022784D1 (no)
DK (1) DK1603910T3 (no)
EA (1) EA008595B1 (no)
ES (1) ES2332132T3 (no)
HK (1) HK1085742A1 (no)
IL (1) IL170468A (no)
MX (1) MXPA05009575A (no)
NO (1) NO20054141L (no)
NZ (1) NZ542136A (no)
PL (1) PL1603910T3 (no)
PT (1) PT1603910E (no)
SI (1) SI1603910T1 (no)
WO (1) WO2004078759A1 (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200813015A (en) * 2006-03-15 2008-03-16 Mitsubishi Pharma Corp 2-(cyclic amino)-pyrimidone derivatives
EP1992624A1 (en) 2007-05-16 2008-11-19 Sanofi-Aventis Heteroarylamide pyrimidone compounds
EP1992625A1 (en) 2007-05-16 2008-11-19 Sanofi-Aventis Arylamide pyrimidone compounds
EP1992620A1 (en) 2007-05-16 2008-11-19 Sanofi-Aventis Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases
EP1992621A1 (en) 2007-05-16 2008-11-19 Sanofi-Aventis Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994460A (en) * 1989-06-01 1991-02-19 Bristol-Myers Squibb Co. Agents for treatment of brain ischemia
US5883254A (en) * 1996-11-08 1999-03-16 Hoffmann-La Roche Inc. Process for making pyrimidine derivatives
EP1136483A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-[Piperazinyl]pyrimidone derivatives
AU2001262150A1 (en) * 2000-03-23 2001-10-03 Mitsubishi Pharma Corporation 2-(nitrogen-heterocyclic)pyrimidone derivatives
ATE309247T1 (de) * 2002-02-28 2005-11-15 Sanofi Aventis Heteroaryl substituierte 2-pyridinyl und 2- pyrimidinyl-6,7,8,9-tetrahydropyrimido(1,2- a)pyrimidin-4-onderivate

Also Published As

Publication number Publication date
MXPA05009575A (es) 2006-05-19
US20060025417A1 (en) 2006-02-02
CA2516934C (en) 2011-09-20
AR043486A1 (es) 2005-08-03
EP1603910A1 (en) 2005-12-14
DE602004022784D1 (de) 2009-10-08
ATE440844T1 (de) 2009-09-15
US7452897B2 (en) 2008-11-18
PL1603910T3 (pl) 2010-02-26
CY1111132T1 (el) 2015-06-11
EA200501243A1 (ru) 2006-04-28
JP4778890B2 (ja) 2011-09-21
JP2006519813A (ja) 2006-08-31
KR20050113218A (ko) 2005-12-01
EA008595B1 (ru) 2007-06-29
AU2004218249A1 (en) 2004-09-16
AU2004218249B2 (en) 2009-04-30
HK1085742A1 (en) 2006-09-01
ES2332132T3 (es) 2010-01-27
WO2004078759A1 (en) 2004-09-16
US20070167455A1 (en) 2007-07-19
SI1603910T1 (sl) 2009-12-31
PT1603910E (pt) 2009-10-30
BRPI0408186A (pt) 2006-04-04
IL170468A (en) 2010-12-30
CA2516934A1 (en) 2004-09-16
NZ542136A (en) 2008-07-31
KR101072159B1 (ko) 2011-10-10
US7211581B2 (en) 2007-05-01
NO20054141L (no) 2005-12-07
DK1603910T3 (da) 2009-11-23
EP1603910B1 (en) 2009-08-26

Similar Documents

Publication Publication Date Title
DK1419152T3 (da) HIV-hæmmende pyrimidin-derivater
DK1594840T3 (da) Piperidin-benzensulfonamid-derivater
DK1549652T3 (da) Kondenserede azolpyrimidinderivater
NO20054136D0 (no) Imidazol-4-yl-etynyl-pyridin-derivater
ATE478870T1 (de) Spiroindolinpiperidinderivate
ATE460418T1 (de) Heterocyclocarboxamidderivate
ATE450506T1 (de) Indol-3-schwefelderivate
ATE467631T1 (de) Chinuclidinamidderivate
IS7720A (is) Píperidín-N-oxíð-afleiður
ATE438644T1 (de) Chinazolinderivate
DK1474408T3 (da) N-Phenyl-2-pyrimidinaminderivater
DK1682493T3 (da) Amidoacetonitrilderivater
ATE512960T1 (de) Pyrimidinderivate
IS8180A (is) Nýjar besímídasólafleiður
ATE352550T1 (de) Chinazolinderivate
IS8364A (is) N-þíasól-2-ýl-bensamíð afleiður
IS8045A (is) Púrín-6-ón-afleiður
DE60307512D1 (de) 3h-chinazoline -4-on derivaten
ATE423771T1 (de) Tetrahydrochinolinderivate
ATE366242T1 (de) 5-substituierte chinazolinonderivate
DK1706373T3 (da) Amidoacetonitrilderivater
NO20054141D0 (no) Substituerte 2-(diaza-bicykloalkyl)pyrimidonderivater
DE50306277D1 (de) 4-alkyl-/4-alkenyl-/4-alkinylmethyl/-1-arylcyclohexylamin-derivate
IS7906A (is) Afleiður própargýl-tríflúorómetoxý-amínó-benzóþíazóls
DK1503988T3 (da) Fredericamycin-derivater

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application